We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Amgen (AMGN - Free Report) ended the recent trading session at $347.94, demonstrating a -1.51% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.11%. On the other hand, the Dow registered a loss of 0.13%, and the technology-centric Nasdaq increased by 0.18%.
Heading into today, shares of the world's largest biotech drugmaker had lost 6.85% over the past month, lagging the Medical sector's loss of 6.43% and the S&P 500's loss of 4.28%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is predicted to post an EPS of $4.74, indicating a 3.27% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $8.51 billion, reflecting a 4.42% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $22.22 per share and revenue of $37.86 billion, which would represent changes of +1.74% and +3.02%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Amgen is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 15.9. Its industry sports an average Forward P/E of 21.19, so one might conclude that Amgen is trading at a discount comparatively.
We can additionally observe that AMGN currently boasts a PEG ratio of 3.52. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.51 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
Amgen (AMGN - Free Report) ended the recent trading session at $347.94, demonstrating a -1.51% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.11%. On the other hand, the Dow registered a loss of 0.13%, and the technology-centric Nasdaq increased by 0.18%.
Heading into today, shares of the world's largest biotech drugmaker had lost 6.85% over the past month, lagging the Medical sector's loss of 6.43% and the S&P 500's loss of 4.28%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is predicted to post an EPS of $4.74, indicating a 3.27% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $8.51 billion, reflecting a 4.42% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $22.22 per share and revenue of $37.86 billion, which would represent changes of +1.74% and +3.02%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Amgen is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 15.9. Its industry sports an average Forward P/E of 21.19, so one might conclude that Amgen is trading at a discount comparatively.
We can additionally observe that AMGN currently boasts a PEG ratio of 3.52. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.51 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.